Trials / Completed
CompletedNCT05763823
A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
A Phase 3, Open Label, Single-Arm Clinical Trial to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) for the Prevention of Clinically Significant Cytomegalovirus (CMV) Infection in Chinese Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of a once-a-day oral or intravenous (IV) dose of Letermovir (MK-8228) in Chinese adult hematopoietic stem cell transplant (HSCT) recipients for the prevention of clinically significant cytomegalovirus (CMV) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Letermovir | Daily 240 mg or 480 mg oral tablets or IV dose |
Timeline
- Start date
- 2023-03-24
- Primary completion
- 2024-04-18
- Completion
- 2024-04-18
- First posted
- 2023-03-10
- Last updated
- 2025-03-25
- Results posted
- 2025-03-25
Locations
21 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05763823. Inclusion in this directory is not an endorsement.